Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2045

Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.

Patents
1,566

Quick answer

1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12286431

    Crystalline forms of a KRas G12C inhibitor

    Mirati Therapeutics, Inc. · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12286480

    Modulators of ROR1-ROR2 binding

    The Regents of the University of California · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12285417

    Methods for treating chronic obstructive pulmonary disease

    Theravance Biopharma R&D IP, LLC · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12286630

    Treatment methods for muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12286405

    Scalable synthesis of dual-target inhibitor of cannabinoid-1 receptor and inducible nitric oxide synthase

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12286395

    Method of synthesis of an ionizable cationic lipid

    ARCTURUS THERAPEUTICS, INC. · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12286402

    Compounds and their use for the treatment of alpha1-antitrypsin deficiency

    CENTESSA PHARMACEUTICALS (UK) LIMITED · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12286400

    Isofagomine salts, methods of use and formulations

    Takeda Pharmaceutical Company Limited · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12285496

    Gene therapy for haploinsufficiency

    The Regents of the University of California · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12285627

    Fabrication and irradiation of a radioactive isotope skin patch

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12285392

    Method for modulating metabolism

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12285447

    Methods and compositions for treating ulcerative colitis

    Finch Therapeutics Holdings LLC · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12285435

    Multivesicular liposome formulations of dexamethasone

    Pacira Pharmaceuticals, Inc. · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12285419

    Bupivacaine multivesicular liposome formulations and uses thereof

    Pacira Pharmaceuticals, Inc. · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12285425

    Glucocorticoid receptor modulators to treat cervical cancer

    Corcept Therapeutics Incorporated · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12285473

    Cancer vaccines targeting MUC16 and uses thereof

    Inovio Pharmaceuticals, Inc. · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12285478

    Foot-and-mouth disease vaccine

    United States of America as represented by the Secretary of the Air Force · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12286479

    Treatment with anti-α4β7 antibody

    Takeda Pharmaceutical Company Limited · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12286406

    Inhibitors of receptor interacting protein kinase I for the treatment of disease

    The Board of Regents of the University of Texas System · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12285424

    Methods for treating neutropenia

    X4 Pharmaceuticals, Inc. · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. WO 2025090898

    ANTICORPS ANTI-RÉCEPTEUR DE LA TRANSFERRINE ET LEURS UTILISATIONS - RÉFÉRENCES CROISÉES AUX DEMANDES CONNEXES

    BIOGEN MA INC [US] · Granted Thu May 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. WO 2025090858

    PROCÉDÉS D'IDENTIFICATION DE VARIANTS DE CAPSIDE DE VAA AYANT DES CARACTÉRISTIQUES SOUHAITÉES

    BIOGEN MA INC [US] · Granted Thu May 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12291508

    Hydrazide containing nuclear transport modulators and uses thereof

    Karyopharm Therapeutics Inc. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12291533

    Substituted fused pyrimidine compounds and uses thereof

    Northwestern University · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12290551

    Methods for imaging and treatment of somatostatin-receptor positive tumors

    Corcept Therapeutics Incorporated · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12290538

    Methods and products for treatment of gastrointestinal disorders

    Finch Therapeutics Holdings LLC · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12291571

    Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12290520

    Methods of use of emulsion formulations of aprepitant

    Heron Therapeutics, Inc. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12290651

    Devices and methods for the treatment of body surface disorders

    Verrica Pharmaceuticals Inc. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12291559

    Compositions and methods for treating cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12291709

    Compositions and methods for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12290505

    Tissue factor-targeted antibody-drug conjugate

    SHANGHAI MIRACOGEN INC. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12290531

    Compositions targeting BCMA and methods of use thereof

    Takeda Pharmaceutical Company Limited · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12292445

    Methods of selecting subjects for treatment with metabolomic modulators

    The Regents of the University of California · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12291576

    Anti-CD45 antibodies and conjugates thereof

    Vor Biopharma Inc. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12292441

    Recombinant Acinetobacter baumannii strain AB5075

    The Government of the United States, as represented by the Secretary of the Army · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12291557

    Chimeric TIM4 receptors and uses thereof

    Cero Therapeutics Holdings, Inc. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12291556

    Parathyroid hormone variants

    Takeda Pharmaceutical Company Limited · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12291565

    Tau binding compounds

    VOYAGER THERAPEUTICS, INC. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12291560

    Dimerizing agent regulated immunoreceptor complexes

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12290596

    Compositions and methods for the treatment of opioid overdose

    Indivior UK Limited · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12291507

    Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency

    CENTESSA PHARMACEUTICALS (UK) LIMITED · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12291502

    Topoisomerase II-alpha inhibitors and methods of treating cancer using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12291058

    Dispersions for additive manufacturing comprising discrete carbon nanotubes

    MOLECULAR REBAR DESIGN, LLC · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12291530

    GLP-1R agonist and therapeutic method thereof

    Ascletis Pharma (China) Co., Limited · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12290567

    Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates

    ARCTURUS THERAPEUTICS, INC. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12290588

    Peptide having activity of improving skin condition and use thereof

    CAREGEN CO., LTD. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12290569

    Methods and compositions using peptides and proteins with c-terminal elements

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2045?

1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.